Johnson & Johnson's Xarelto Delay Likely: Analyst
By IB Times Staff Reporter | September 12, 2011 11:51 PM EST
Despite the FDA advisory panel's backing, RBC Capital Markets does not believe Johnson & Johnson's (NYSE: JNJ) Xarelto is well positioned to receive marketing approval on Nov. 5.
On Sept. 8, the Cardiovascular and Renal Drugs Advisory Committee (AdCom) recommended approval of Xarelto (9-2; 1 abstention) for stroke prevention in atrial fibrillation (SPAF).
"While the FDA will consider the panel’s recommendation, it is not binded to follow it. Given the mixed tone of the briefing documents and call for a complete response letter, we suspect a delay in final approval is likely," said Glenn Novarro, an analyst at RBC Capital Markets.
The committee debated the issues raised initially by FDA reviewers: difficulty in assessing efficacy of Xarelto (not used as "skillfully" in ROCKET versus RE-LY), excess event rates when Xarelto is discontinued (concern over how to transition patients to warfarin), and optimal Xarelto dosing (2 time a day versus once a day).
Additionally, a call for an additional pre-approval substudy would delay final approval. Novarro said unanswered questions linger post AdCom meeting.
Recall, Pfizer Inc./Bristol Myers Squibb Co. presented the complete results from the ARISTOTLE trial at the European Society of Cardiology (ESC) meeting on Aug. 28.
Eliquis reduced the risk of stroke by 21 percent (versus 12 percent reduction in the ITT analysis in ROCKET-AF), major bleeding by 31 percent (versus 3 percent increase in ROCKET-AF), and mortality by 11 percent (versus 13 percent for ROCKET-AF, however, this measure was not statistically significant).
Additionally, the warfarin arm was well-controlled with a TTR mean of 62 percent (versus 55 percent TTR in ROCKET-AF). Given the strong data, Xarelto will likely lose share once Eliquis comes to market (late third quarter/early fourth quarter U.S. filing).
SPAF is a major indication for Xarelto (model reflects more than 50 percent of Xarelto sales). For 2012, the brokerage lowered its U.S. Xarelto estimate to $135 million from $375 million. It now expects sales to grow to $875 million by 2015, down from previous estimate of $1.02 billion.
Novarro said his new model assumes Xarelto launches in the U.S. for the SPAF indication in late-2012. His 2012 EPS estimate is reduced by $0.02 to $5.30 that excludes the Synthes deal.
Johnson & Johnson stock is currently trading down 1.37 percent at $62.77 on the NYSE at 9:31 am EDT.
To contact the editor, e-mail:
Most Popular Slideshows
- NFL MNF: Pittsburgh Steelers 30, Houston Texans 23 [PHOTOS]
- 2014 MLB World Series Game 1: San Francisco Giants 7, Kansas City Royals 1 [PHOTOS]
- 2014 MLB World Series - Game 2: Kansas City Royals 7, San Francisco Giants 2 [PHOTOS]
- NFL Thursday Recap - Denver Broncos 35, San Diego Chargers 21: Peyton Manning Has 3 TDs In Easy Win [PHOTOS]
Join the Conversation
- Xiaomi Redmi 1S vs. Sharp Aquos Crystal – Specifications, Features And Price Showdown
- ASUS Releases A Teaser Indicating The Arrival of New Zenfone and ZenWatch On October 28
- Boy Stoned To Death For Alleged Rape, Victim Receives Dowry From Militants
- Three Dual SIM Samsung Galaxy Note 4 Duos Variants Comes To China
- Russia is Creating Underwater Combat Robots to Protect its Arctic Territories
- Update HTC One M7 with LG G2 with Android 4.4.2 as Sprint OTA: Fixes and Installation
- ‘Lone Wolf’ Attack on Canada Parliament Hill Could be ISIS-Related